Published in Antimicrob Agents Chemother on January 01, 1987
Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy. Br J Pharmacol (2006) 1.25
Inhibition of varicella-zoster virus-induced DNA polymerase by a new guanosine analog, 9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine triphosphate. Antimicrob Agents Chemother (1988) 1.10
Pharmacokinetics and antiviral activity in simian varicella virus-infected monkeys of (R,S)-9-[4-hydroxy-2-(hydroxymethyl) butyl]guanine, an anti-varicella-zoster virus drug. Antimicrob Agents Chemother (1988) 1.00
Mode of action of (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine against herpesviruses. Antimicrob Agents Chemother (1995) 1.00
Inhibition of human herpesvirus 6 replication by 9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine (2HM-HBG) and other antiviral compounds. Antimicrob Agents Chemother (1990) 0.95
Efficacy of (-)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine in African green monkeys infected with simian varicella virus. Antimicrob Agents Chemother (1993) 0.86
Improvement of the absorption of oral (R,S)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine, an anti-varicella-zoster virus drug, in rats and monkeys. Antimicrob Agents Chemother (1989) 0.85
Antiherpesvirus activity and mechanism of action of indolo-(2,3-b)quinoxaline and analogs. Antimicrob Agents Chemother (1988) 0.84
Selection and characterization of varicella-zoster virus variants resistant to (R)-9-[4-hydroxy-2-(hydroxymethy)butyl]guanine. Antimicrob Agents Chemother (2001) 0.81
Current and Potential Treatments for Ubiquitous but Neglected Herpesvirus Infections. Chem Rev (2014) 0.80
The antiherpesvirus activity of H2G [(R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine] is markedly enhanced by the novel immunosuppressive agent mycophenolate mofetil. Antimicrob Agents Chemother (1998) 0.77
Effect of (r)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine (H2G) and AZT-lipid-PFA on human herpesvirus-6B infected cells. J Clin Virol (2009) 0.75
Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci U S A (1977) 11.20
Human deoxythymidine kinase. I. Purification and general properties of the cytoplasmic and mitochondrial isozymes derived from blast cells of acute myelocytic leukemia. J Biol Chem (1976) 2.78
Gel electrophoresis and isoelectric focusing of mitochondrial and viral-induced thymidine kinases. Int J Cancer (1974) 2.20
Trisodium phosphonoformate, a new antiviral compound. Science (1978) 2.13
Properties of mitochondrial thymidine kinases of parental and enzyme-deficient HeLa cells. Arch Biochem Biophys (1973) 1.68
Influence of cells and virus multiplicity on the inhibition of herpesviruses with acycloguanosine. Intervirology (1980) 1.50
Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine. N Engl J Med (1986) 1.39
An assay for pyrimidine deoxyribonucleoside kinase using gamma-32P-labeled ATP. Anal Biochem (1975) 1.34
Induction of thymidine kinase and DNase in varicella-zoster virus-infected cells and kinetic properties of the virus-induced thymidine kinase. J Virol (1979) 1.33
Intracellular pools of thymidine reduce the antiviral action of acyclovir. Intervirology (1983) 1.16
Deoxypyrimidine nucleoside metabolism in varicella-zoster virus-infected cells. J Virol (1978) 1.16
Reversible inhibition of cytomegalovirus replication by phosphonoformate. Intervirology (1980) 1.02
Computer-based virus sensitivity assay and neutralization method. Applications for herpesviruses. J Virol Methods (1983) 1.02
Inhibitory effects of foscarnet on herpesvirus multiplication in cell culture. Arch Virol (1981) 0.99
Development of sensitive and enzyme-linked immunoassays for herpesvirus antigens and some applications. Dev Biol Stand (1982) 0.97
Acyclic guanosine analogs as substrates for varicella-zoster virus thymidine kinase. Antimicrob Agents Chemother (1986) 0.90
Interactions between virus and antiviral compounds in the host cell. Med Biol (1984) 0.88
A mutant strain of varicella-zoster virus deficient in thymidine kinase-inducing activity. Fukushima J Med Sci (1983) 0.87
Influence of cell culture conditions on the inhibition of herpes simplex virus type 1 replication by acyclovir. Intervirology (1982) 0.87
Rapid diagnosis of varicella-zoster virus infection by detection of viral deoxythymidine kinase in serum and vesicle fluid. J Clin Microbiol (1983) 0.82
Cerebral ventriculitis associated with Achromobacter xylosoxidans. J Clin Pathol (1978) 2.86
Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group. Lancet (1999) 2.74
Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob Agents Chemother (1977) 2.71
Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro. Antiviral Res (1987) 2.27
Pseudomonas cepacia typing systems: collaborative study to assess their potential in epidemiologic investigations. Rev Infect Dis (1989) 2.25
Cytomegalovirus DNA detection in sera from patients with active cytomegalovirus infections. J Clin Microbiol (1992) 2.14
Random albumin/creatinine ratio for quantification of proteinuria in manifest pre-eclampsia. BJOG (2006) 2.13
Trisodium phosphonoformate, a new antiviral compound. Science (1978) 2.13
Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol (1998) 2.06
Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection. J Virol (1987) 1.99
Congenital hypothyroidism in Sweden. Incidence and age at diagnosis. Acta Paediatr Scand (1978) 1.94
Acute hemorrhagic cystitis in children. Isolation of adenovirus type II. N Engl J Med (1968) 1.90
Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet (1998) 1.80
An interchangeable ELISA for cytomegalovirus antigen and antibody. J Virol Methods (1981) 1.80
Virus-specific antibody activity of different subclasses of immunoglobulins G and A in cytomegalovirus infections. Infect Immun (1983) 1.78
Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins. Proc Natl Acad Sci U S A (1992) 1.77
Hypocalcemia and parathyroid hormone secretion in critically ill patients. Crit Care Med (2000) 1.73
Rapid "tea-bag" peptide synthesis using 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids applied for antigenic mapping of viral proteins. Immunol Lett (1991) 1.73
Mode of action, toxicity, pharmacokinetics, and efficacy of some new antiherpesvirus guanosine analogs related to buciclovir. Antimicrob Agents Chemother (1986) 1.71
Neutralizing cross-reactive and non-neutralizing monoclonal antibodies to HIV-1 gp120. AIDS (1990) 1.71
Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system. Lancet (1993) 1.68
Enzymatic synthesis of deoxyribonucleotides. X. Reduction of purine ribonucleotides; allosteric behavior and substrate specificity of the enzyme system from Escherichia coli B. J Biol Chem (1966) 1.64
Significance of ribonucleotide reduction in the biosynthesis of deoxyribonucleotides in Escherichia coli. Eur J Biochem (1967) 1.63
Human immunodeficiency virus type 1 p24 production and antigenic variation in tissue culture of isolates with various growth characteristics. J Med Virol (1989) 1.61
Cooperativity of neutralizing antibodies directed against the V3 and CD4 binding regions of the human immunodeficiency virus gp120 envelope glycoprotein. J Acquir Immune Defic Syndr (1992) 1.57
Genotyping is a valuable diagnostic complement to neonatal screening for congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab (1999) 1.56
Antibodies mediating cellular cytotoxicity and neutralization correlate with a better clinical stage in children born to human immunodeficiency virus-infected mothers. J Infect Dis (1990) 1.54
Virus-specific immunoglobulin G subclasses in herpes simplex and varicella-zoster virus infections. J Clin Microbiol (1984) 1.53
Subclass reactivity to Epstein-Barr virus capsid antigen in primary and reactivated EBV infections. J Med Virol (1987) 1.52
Glutathione synthetase deficiency, an inborn error of metabolism involving the gamma-glutamyl cycle in patients with 5-oxoprolinuria (pyroglutamic aciduria). Proc Natl Acad Sci U S A (1974) 1.51
Arthritis in DBA/1 mice induced with passively transferred type II collagen immune serum. Immunohistopathology and serum levels of anti-type II collagen auto-antibodies. Scand J Immunol (1990) 1.51
The odontogenic keratocyst: a benign cystic tumor? J Oral Maxillofac Surg (1984) 1.51
Influence of cells and virus multiplicity on the inhibition of herpesviruses with acycloguanosine. Intervirology (1980) 1.50
Primary Sjögren's syndrome in patients with multiple sclerosis. Neurology (1992) 1.49
Active smoking and a history of smoking are associated with enhanced prostaglandin F(2alpha), interleukin-6 and F2-isoprostane formation in elderly men. Atherosclerosis (2005) 1.49
Comparative efficacy of antiherpes drugs against various strains of varicella-zoster virus. J Infect Dis (1983) 1.47
Identification of the stable free radical tyrosine residue in ribonucleotide reductase. EMBO J (1986) 1.47
Parvovirus B19 infection: association with third-trimester intrauterine fetal death. BJOG (2000) 1.47
Automated pre-ejection period variation indexed to tidal volume predicts fluid responsiveness after cardiac surgery. Acta Anaesthesiol Scand (2009) 1.46
Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents. J Med Chem (1995) 1.43
Sequence variation within three important cytomegalovirus gene regions in isolates from four different patient populations. J Clin Microbiol (1998) 1.43
The European Union Directive on Clinical Research: present status of implementation in EU member states' legislations with regard to the incompetent patient. Intensive Care Med (2005) 1.42
Uncompensated blood loss is not tolerated during acute normovolemic hemodilution in anesthetized pigs. Anesth Analg (1998) 1.42
Dynamic changes in HIV-1 quasispecies from azidothymidine (AZT)-treated patients. FASEB J (1992) 1.41
Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in posttreatment sera. J Virol (1992) 1.39
Isolation and characterization of calf liver thioredoxin. J Biol Chem (1974) 1.39
Risk of cytomegalovirus infection after peripheral blood stem cell transplantation. Bone Marrow Transplant (1997) 1.38
Appearance of immunoglobulin G Fc receptor in cultured human cells infected with varicella-zoster virus. Infect Immun (1979) 1.38
Comparative activities of several nucleoside analogs against duck hepatitis B virus in vitro. Antimicrob Agents Chemother (1990) 1.38
Gastrointestinal transit of amoxicillin modified-release tablets and a placebo tablet including pharmacokinetic assessments of amoxicillin. Scand J Gastroenterol (1996) 1.38
Altered brain white matter integrity in healthy carriers of the APOE epsilon4 allele: a risk for AD? Neurology (2006) 1.38
Regional variations of iodine nutrition and thyroid function during the neonatal period in Europe. Biol Neonate (1986) 1.37
Evidence for two different classes of redox-active cysteines in ribonucleotide reductase of Escherichia coli. J Biol Chem (1989) 1.36
Missense mutations in the human glutathione synthetase gene result in severe metabolic acidosis, 5-oxoprolinuria, hemolytic anemia and neurological dysfunction. Hum Mol Genet (1997) 1.36
Antiherpetic activity and mechanism of action of 9-(4-hydroxybutyl)guanine. Antiviral Res (1983) 1.35
4'-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro. Antimicrob Agents Chemother (2001) 1.35
Pyrophosphate analogues as inhibitors of herpes simplex virus type 1 DNA polymerase. Biochim Biophys Acta (1980) 1.34
Inhibition of gamma-glutamylcysteine synthetase by cystamine: an approach to a therapy of 5-oxoprolinuria (pyroglutamic aciduria). Biochem Biophys Res Commun (1977) 1.34
Antibody dependent cytolytic effector lymphocytes (K cells) in human blood. J Reticuloendothel Soc (1975) 1.33
Pyrophosphate analogues as inhibitors of DNA polymerases of cytomegalovirus, herpes simplex virus and cellular origin. Biochim Biophys Acta (1982) 1.33
The timing of glucocorticoid administration in rheumatoid arthritis. Ann Rheum Dis (1997) 1.33
Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies. J Virol (1993) 1.32
Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients. J Antimicrob Chemother (1986) 1.31
Antiviral activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4- carboxamide and related compounds. Antimicrob Agents Chemother (1991) 1.30
Inhibitory effect of glycyrrhizin on the in vitro infectivity and cytopathic activity of the human immunodeficiency virus [HIV (HTLV-III/LAV)]. Antiviral Res (1987) 1.30
Diagnosis of infectious mononucleosis by the monospot test. Am J Clin Pathol (1969) 1.28
Clinical and subclinical reactivations of varicella-zoster virus in immunocompromised patients. J Infect Dis (1986) 1.28
Enzymatic synthesis of deoxyribonucleotides. IX. Allosteric effects in the reduction of pyrimidine ribonucleotides by the ribonucleoside diphosphate reductase system of Escherichia coli. J Biol Chem (1966) 1.27
Characterisation of a linear binding site for a monoclonal antibody to hepatitis B core antigen. J Med Virol (1991) 1.26
Evaluation of enzyme-linked immunosorbent assays with two synthetic peptides of Epstein-Barr virus for diagnosis of infectious mononucleosis. J Infect Dis (1990) 1.25
Nucleic acid hybridization, a method to determine effects of antiviral compounds on herpes simplex virus type 1 DNA synthesis. Antiviral Res (1984) 1.25
Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients. Scand J Infect Dis (1985) 1.25
Altered deactivation in individuals with genetic risk for Alzheimer's disease. Neuropsychologia (2008) 1.25
Analysis of oligonucleotide probe affinities using surface plasmon resonance: a means for mutational scanning. Anal Biochem (1997) 1.24
Glycerol production in subcutaneous adipose tissue in lean and obese humans. J Clin Invest (1992) 1.24
Mechanism of selective inhibition of human immunodeficiency virus by ingenol triacetate. Antimicrob Agents Chemother (1996) 1.24
Incidence of congenital hypothyroidism: retrospective study of neonatal laboratory screening versus clinical symptoms as indicators leading to diagnosis. Br Med J (Clin Res Ed) (1984) 1.23
Restricted IgG subclass responses to HTLV-III/LAV and to cytomegalovirus in patients with AIDS and lymphadenopathy syndrome. J Infect Dis (1986) 1.22
Variations in the cytomegalovirus major immediate-early gene found by direct genomic sequencing. J Clin Microbiol (1992) 1.22
Evaluation of Gentian cystatin C reagent on Abbott Ci8200 and calculation of glomerular filtration rate expressed in mL/min/1.73 m(2) from the cystatin C values in mg/L. Scand J Clin Lab Invest (2007) 1.21
Critical determinants of antiherpes efficacy of buciclovir and related acyclic guanosine analogs. Antiviral Res (1987) 1.21
Inhibitory effects of selected antiviral compounds on human hepatitis B virus DNA synthesis. Antimicrob Agents Chemother (1991) 1.21
T and B cell responses of Plasmodium falciparum malaria-immune individuals to synthetic peptides corresponding to sequences in different regions of the P. falciparum antigen Pf155/RESA. J Immunol (1989) 1.21
A monoclonal antibody to human immunodeficiency virus type 1 which mediates cellular cytotoxicity and neutralization. J Virol (1990) 1.21
Design and evaluation of pilicides: potential novel antibacterial agents directed against uropathogenic Escherichia coli. Chembiochem (2001) 1.20
IgG antibodies to human herpesvirus-6 in children and adults and in primary Epstein-Barr virus infections and cytomegalovirus infections [corrected]. J Virol Methods (1988) 1.20
Cytomegalovirus infection of the central nervous system in patients with AIDS: diagnosis by DNA amplification from cerebrospinal fluid. J Infect Dis (1992) 1.20
Study of Fab and F(ab') 2 from rabbit IgG for capacity to induce lymphocyte-mediated target cell destruction in vitro. Int Arch Allergy Appl Immunol (1972) 1.20
Metabolism and mode of action of (R)-9-(3,4-dihydroxybutyl)guanine in herpes simplex virus-infected vero cells. J Biol Chem (1986) 1.20
Pyroglutamic aciduria (5-oxoprolinuria), an inborn error in glutathione metabolism. Pediatr Res (1974) 1.19
A novel method for determining the sensitivity of herpes simplex virus to antiviral compounds. J Virol Methods (1983) 1.19
A new peptide for human parvovirus B19 antibody detection. Scand J Infect Dis (1989) 1.19
Selective inhibitory effect of (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and 2'-nor-cyclic GMP on adenovirus replication in vitro. Antimicrob Agents Chemother (1987) 1.19
Routine oxytocin in the third stage of labour: a placebo controlled randomised trial. Br J Obstet Gynaecol (1997) 1.19
9-(3,4-dihydroxybutyl)guanine, a new inhibitor of herpesvirus multiplication. Antimicrob Agents Chemother (1983) 1.18